Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers | Zendy

Akil Jackson | Zendy; Antonio D’Avolio | Zendy; Graeme Moyle | Zendy; Stefano Bonora | Zendy; Giovanni Di Perri | Zendy; Laura Else | Zendy; Marco Simiele | Zendy; Gurmit Jagjit Singh | Zendy; David Back | Zendy; Marta Boffito | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers

Author(s) -

Akil Jackson,

Antonio D’Avolio,

Graeme Moyle,

Stefano Bonora,

Giovanni Di Perri,

Laura Else,

Marco Simiele,

Gurmit Jagjit Singh,

David Back,

Marta Boffito

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku060

Subject(s) - boceprevir , medicine , hypericum perforatum , pharmacokinetics , pharmacology , hepatitis c virus , ribavirin , virology , virus

St John's wort (SJW; Hypericum perforatum) induces CYP3A4 that is involved in the metabolism of the hepatitis C virus (HCV) protease inhibitor boceprevir. Reduced boceprevir exposure and efficacy would contribute to therapeutic failure and increase the risk for resistance development. Boceprevir is co-administered with interferon/ribavirin, and depression has been described frequently in patients undergoing HCV treatment. Patients may purchase over-the-counter herbals to manage depression, and knowing the interaction between SJW and boceprevir is desirable.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research